MX2017007814A - Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico. - Google Patents
Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.Info
- Publication number
- MX2017007814A MX2017007814A MX2017007814A MX2017007814A MX2017007814A MX 2017007814 A MX2017007814 A MX 2017007814A MX 2017007814 A MX2017007814 A MX 2017007814A MX 2017007814 A MX2017007814 A MX 2017007814A MX 2017007814 A MX2017007814 A MX 2017007814A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- polycyclic
- pharmaceutical use
- carbamoylpyridone compounds
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuesto para uso en el tratamiento de infección por virus de inmunodeficiencia humana (VIH). Los compuestos tienen la siguiente Fórmula (Ia): (ver Fórmula) (Ia) incluyendo estereoisómeros y sales farmacéuticamente aceptables de los mismos, en donde A´, R1, R2 y R3 son como se define en la presente. También se describen métodos asociados con la reparación y uso de tales compuestos, así como composiciones farmacéuticas que comprenden tales compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096291P | 2014-12-23 | 2014-12-23 | |
PCT/US2015/067155 WO2016106237A1 (en) | 2014-12-23 | 2015-12-21 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017007814A true MX2017007814A (es) | 2017-09-18 |
Family
ID=55168426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017007814A MX2017007814A (es) | 2014-12-23 | 2015-12-21 | Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico. |
Country Status (24)
Country | Link |
---|---|
US (4) | US9522912B2 (es) |
EP (2) | EP3237416B1 (es) |
JP (3) | JP6393835B2 (es) |
KR (4) | KR101978167B1 (es) |
CN (2) | CN107108643B (es) |
AR (1) | AR103251A1 (es) |
AU (3) | AU2015369817B2 (es) |
BR (1) | BR102015032109A2 (es) |
CA (1) | CA2969244C (es) |
EA (1) | EA201791019A1 (es) |
ES (1) | ES2732482T3 (es) |
HK (1) | HK1244000B (es) |
IL (1) | IL252532A0 (es) |
MA (1) | MA45613A (es) |
MX (1) | MX2017007814A (es) |
NZ (1) | NZ732391A (es) |
PL (1) | PL3237416T3 (es) |
PT (1) | PT3237416T (es) |
SG (1) | SG11201704421QA (es) |
SI (1) | SI3237416T1 (es) |
TR (1) | TR201909152T4 (es) |
TW (2) | TWI695003B (es) |
UY (1) | UY36465A (es) |
WO (1) | WO2016106237A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD4736C1 (ro) | 2012-12-21 | 2021-07-31 | Gilead Sciences, Inc. | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
PL3277691T3 (pl) * | 2015-04-02 | 2019-07-31 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
WO2019090081A1 (en) * | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
BR112020008834A2 (pt) | 2017-11-02 | 2020-12-22 | Calico Life Sciences Llc | Moduladores da via de estresse integrada |
AU2018378832B9 (en) | 2017-12-07 | 2021-05-27 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
EP3723751A4 (en) * | 2017-12-08 | 2021-07-07 | The Rockefeller University | PYRANO [3,4-B] PYRAZIN-KAPPA-OPIOID RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION, PRURITUS, PAIN AND INFLAMMATION |
KR20210015922A (ko) | 2018-05-31 | 2021-02-10 | 시오노기 앤드 컴파니, 리미티드 | 다환성 카바모일피리돈 유도체 |
MX2020012185A (es) | 2018-05-31 | 2021-01-29 | Shionogi & Co | Derivado policiclico de piridona. |
WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
WO2021093846A1 (zh) * | 2019-11-13 | 2021-05-20 | 上海拓界生物医药科技有限公司 | 新型四环杂环化合物及其药物用途 |
WO2021107066A1 (ja) * | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | インテグラーゼ阻害剤及び抗hiv薬を組み合わせることを特徴とするhiv感染症の予防及び治療用医薬 |
WO2021107065A1 (ja) * | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | 多環性ピリドピラジン誘導体 |
CN115151545A (zh) | 2020-02-24 | 2022-10-04 | 吉利德科学公司 | 用于治疗hiv感染的四环化合物 |
MX2023008137A (es) | 2021-01-19 | 2023-07-21 | Gilead Sciences Inc | Compuestos de piridotriazina sustituidos y usos de estos. |
CN114736173A (zh) * | 2022-05-24 | 2022-07-12 | 无锡捷化医药科技有限公司 | 一种3-(二氟甲基)氧杂环丁烷-3-胺盐酸盐的制备方法 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
WO2000039086A1 (fr) | 1998-12-25 | 2000-07-06 | Shionogi & Co., Ltd. | Composes heterocycliques aromatiques possedant des activites inhibitrices de l'integrase du vih |
AU2001262732A1 (en) | 2000-06-14 | 2001-12-24 | Shionogi And Co., Ltd. | Inhibitor for enzyme having two divalent metal ions as active centers |
KR20100087209A (ko) | 2001-08-10 | 2010-08-03 | 시오노기세이야쿠가부시키가이샤 | 항바이러스제 |
KR20040048936A (ko) | 2001-10-03 | 2004-06-10 | 유씨비 소시에떼아노님 | 피롤리디논 유도체 |
RS51542B (sr) | 2001-10-26 | 2011-06-30 | Istituto Di Ricerche Di Biologia Molecolare P.Angeletti Spa. | N-supstituisani hidroksipirimidinon karboksamidni inhibitori hiv integraze |
AU2003248872A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
US7517532B2 (en) | 2002-09-11 | 2009-04-14 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors |
EP4059923A1 (en) | 2002-11-20 | 2022-09-21 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
JP2006508589A (ja) * | 2002-11-26 | 2006-03-09 | アンビエント・コーポレイション | パワーライン伝送のための誘導カップラの構成体 |
AU2004206821C1 (en) | 2003-01-14 | 2009-10-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
US20070155744A1 (en) | 2004-01-30 | 2007-07-05 | Istituto Di Ricerche Di Biologia Molecolare P, Angeletti S.P.A. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors |
JP2007528396A (ja) | 2004-03-09 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬 |
WO2005110415A1 (en) | 2004-05-07 | 2005-11-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
WO2005113509A1 (en) | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
EP3287130A1 (en) | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
EP2258376B1 (en) | 2004-07-27 | 2019-02-27 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
EP1790638B1 (en) | 2004-09-15 | 2013-04-03 | Shionogi Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
WO2006066414A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
ATE516026T1 (de) | 2005-02-21 | 2011-07-15 | Shionogi & Co | Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung |
PL3045206T3 (pl) | 2005-04-28 | 2018-08-31 | Viiv Healthcare Company | Wielopierścieniowe pochodne karbamoilopirydonu wykazujące aktywność inhibitorową wobec integrazy HIV |
US20060249072A1 (en) * | 2005-05-05 | 2006-11-09 | Csillag Frank J | Method of synthesizing a fluoride growth material for improved outgassing |
WO2006125048A2 (en) | 2005-05-16 | 2006-11-23 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
JP2009502964A (ja) | 2005-07-27 | 2009-01-29 | ギリアード サイエンシーズ, インコーポレイテッド | Hivを阻害するための抗ウイルス性ホスホン酸結合体 |
TW200800988A (en) * | 2005-10-27 | 2008-01-01 | Shionogi & Amp Co Ltd | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
SG170796A1 (en) | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc Us | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
EP2452682A1 (en) | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
WO2007102499A1 (ja) | 2006-03-06 | 2007-09-13 | Japan Tobacco Inc. | 4-オキソキノリン化合物の製造方法 |
AU2007223260C1 (en) | 2006-03-06 | 2011-02-03 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
EP2046328A4 (en) | 2006-07-19 | 2009-10-28 | Univ Georgia Res Found | PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY |
CN105315154A (zh) | 2006-09-12 | 2016-02-10 | 吉里德科学公司 | 制备整合酶抑制剂的方法和中间体 |
WO2008048538A1 (en) | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
EA019893B1 (ru) | 2007-02-23 | 2014-07-30 | Джилид Сайэнс, Инк. | Фармацевтическая композиция и способ лечения вич-инфекции |
US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
SG182229A1 (en) | 2007-06-29 | 2012-07-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
CN101743004A (zh) | 2007-06-29 | 2010-06-16 | 吉里德科学公司 | 治疗用组合物及其用途 |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
EP2220046B1 (en) | 2007-11-16 | 2014-06-18 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2010011813A1 (en) | 2008-07-23 | 2010-01-28 | Alkermes, Inc. | Complex of trospium and pharmaceutical compositions thereof |
WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
KR101695807B1 (ko) | 2008-07-25 | 2017-01-13 | 비이브 헬쓰케어 컴퍼니 | 화합물 |
WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
EP2320908B9 (en) | 2008-07-25 | 2014-06-18 | VIIV Healthcare Company | Dolutegravir Prodrugs |
WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
EP2330902B1 (en) | 2008-07-25 | 2012-11-14 | GlaxoSmithKline LLC | Chemical compounds |
US8624023B2 (en) | 2008-12-11 | 2014-01-07 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
CA2745071C (en) * | 2008-12-17 | 2018-08-28 | Yufang Xiao | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
TR201807704T4 (tr) | 2010-01-27 | 2018-06-21 | Viiv Healthcare Co | Anti-viral tedavi. |
TW201139437A (en) | 2010-02-26 | 2011-11-16 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative and use of the same as HIV integrase inhibitor |
TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
CN103209963A (zh) | 2010-07-02 | 2013-07-17 | 吉里德科学公司 | 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物 |
AP2013006706A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat AIDS |
CN103154004B (zh) | 2010-08-05 | 2016-07-06 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的化合物的制造方法 |
TR201810736T4 (tr) | 2010-09-24 | 2018-08-27 | Shionogi & Co | Substitüe polisiklik karbamoil piridon derivatı ön-ilacı. |
ES2707997T3 (es) | 2011-04-21 | 2019-04-08 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmacéutico |
US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
JP6205354B2 (ja) | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のための化合物 |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
EP2742051B1 (en) | 2011-09-14 | 2016-10-12 | Mapi Pharma Limited | Amorpous form of the dolutegravir sodium salt |
CA2851218A1 (en) | 2011-10-12 | 2013-04-18 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
WO2013091096A1 (en) | 2011-12-20 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Condensed triclyclic compounds as inhibitors of hiv replication |
WO2013103738A1 (en) * | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
JP5911638B2 (ja) | 2012-04-20 | 2016-04-27 | ギリアード サイエンシーズ, インコーポレイテッド | ベンゾチアゾール−6−イル酢酸誘導体およびhiv感染を処置するためのそれらの使用 |
WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
WO2014014933A1 (en) | 2012-07-20 | 2014-01-23 | Merck Sharp & Dohme Corp. | Hiv treatment with amido-substituted pyrimidinone derivatives |
WO2014018449A1 (en) | 2012-07-25 | 2014-01-30 | Merck Sharp & Dohme Corp. | Substituted naphthyridinedione derivatives as hiv integrase inhibitors |
SG11201500812QA (en) | 2012-08-03 | 2015-04-29 | Gilead Sciences Inc | Process and intermediates for preparing integrase inhibitors |
MX2015007563A (es) | 2012-12-14 | 2015-10-14 | Glaxosmithkline Llc | Composiciones farmaceuticas. |
US9714243B2 (en) * | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
MD4736C1 (ro) | 2012-12-21 | 2021-07-31 | Gilead Sciences, Inc. | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia |
US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
WO2014100077A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Gastro-retentive formulations |
AR094311A1 (es) | 2012-12-27 | 2015-07-22 | Japan Tobacco Inc | Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv |
WO2014172188A2 (en) * | 2013-04-16 | 2014-10-23 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
EP3008044B1 (en) * | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
ES2768658T3 (es) | 2013-09-27 | 2020-06-23 | Merck Sharp & Dohme | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del VIH |
WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
PL3277691T3 (pl) * | 2015-04-02 | 2019-07-31 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne |
-
2015
- 2015-12-10 TW TW104141539A patent/TWI695003B/zh active
- 2015-12-10 TW TW109115099A patent/TWI738321B/zh active
- 2015-12-21 MX MX2017007814A patent/MX2017007814A/es unknown
- 2015-12-21 AU AU2015369817A patent/AU2015369817B2/en active Active
- 2015-12-21 KR KR1020177020150A patent/KR101978167B1/ko active IP Right Grant
- 2015-12-21 CN CN201580070876.6A patent/CN107108643B/zh active Active
- 2015-12-21 KR KR1020217010577A patent/KR20210042185A/ko not_active Application Discontinuation
- 2015-12-21 CN CN202010421213.7A patent/CN111454273A/zh active Pending
- 2015-12-21 CA CA2969244A patent/CA2969244C/en active Active
- 2015-12-21 PL PL15825729T patent/PL3237416T3/pl unknown
- 2015-12-21 EP EP15825729.5A patent/EP3237416B1/en active Active
- 2015-12-21 PT PT15825729T patent/PT3237416T/pt unknown
- 2015-12-21 BR BR102015032109A patent/BR102015032109A2/pt not_active Application Discontinuation
- 2015-12-21 WO PCT/US2015/067155 patent/WO2016106237A1/en active Application Filing
- 2015-12-21 MA MA045613A patent/MA45613A/fr unknown
- 2015-12-21 KR KR1020197013162A patent/KR102020004B1/ko active IP Right Grant
- 2015-12-21 JP JP2017531320A patent/JP6393835B2/ja active Active
- 2015-12-21 NZ NZ732391A patent/NZ732391A/en not_active IP Right Cessation
- 2015-12-21 EA EA201791019A patent/EA201791019A1/ru unknown
- 2015-12-21 UY UY0001036465A patent/UY36465A/es not_active Application Discontinuation
- 2015-12-21 TR TR2019/09152T patent/TR201909152T4/tr unknown
- 2015-12-21 US US14/977,347 patent/US9522912B2/en active Active
- 2015-12-21 SG SG11201704421QA patent/SG11201704421QA/en unknown
- 2015-12-21 ES ES15825729T patent/ES2732482T3/es active Active
- 2015-12-21 KR KR1020197025726A patent/KR102240584B1/ko active IP Right Grant
- 2015-12-21 EP EP18173776.8A patent/EP3388431A1/en active Pending
- 2015-12-21 SI SI201530743T patent/SI3237416T1/sl unknown
- 2015-12-22 AR ARP150104261A patent/AR103251A1/es unknown
-
2016
- 2016-11-11 US US15/349,353 patent/US9795602B2/en active Active
-
2017
- 2017-05-25 IL IL252532A patent/IL252532A0/en unknown
- 2017-09-14 US US15/704,842 patent/US10646486B2/en active Active
-
2018
- 2018-03-12 HK HK18103442.8A patent/HK1244000B/zh unknown
- 2018-07-20 JP JP2018136915A patent/JP6934846B2/ja active Active
-
2019
- 2019-01-22 AU AU2019200422A patent/AU2019200422B2/en active Active
-
2020
- 2020-01-07 JP JP2020000897A patent/JP2020073560A/ja active Pending
- 2020-03-27 US US16/832,230 patent/US20210015816A1/en not_active Abandoned
- 2020-12-10 AU AU2020286299A patent/AU2020286299B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017007814A (es) | Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico. | |
MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
PH12016500389B1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MX2017010506A (es) | Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. | |
NZ741957A (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
PH12015501156A1 (en) | Pharmaceutical compositions | |
AU2018253590A1 (en) | Imidazopyridazine compounds | |
TN2015000293A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
EA033921B9 (ru) | Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа |